AKI causes high mortality and morbidity, especially in critically ill patients, and prolongs the patient's stay in the intensive care unit. Due to the high morbidity and mortality associated with AKI, many researchers are studying several new biomarkers for earlier detection of AKI, determination of etiologies, and prediction of outcomes. However, the use of these new biomarkers may be limited due to reimbursement issues. In addition to the therapeutic role of furosemide in fluid balance, blood pressure control, and hypercalcemia management, Chawla et al. recommend the furosemide stress test (FST) as a tool to predict AKI progression. Designing a test that predicts the probability of AKI progression will help us make better decisions regarding the optimal timing of RRT initiation. In this study, we aimed to evaluate the feasibility of using the FST test in determining the progression of AKI in patients hospitalized in the intensive care unit and the need for RRT using the noninvasive procedure furosemide stress test.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Those who meet KDIGO AKI stage 1 and stage 2 criteria in the first 24 hours
. Those with sufficient fluid volume (CVP≥6 cmH20)
. Female and male patients over the age of 18 will be included in the study
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial looked at using a furosemide stress test to predict whether acute kidney injury (AKI) would get worse to Stage 3 — can you explain what that test actually involves and whether it's something that's already being used in your ICU based on findings like these?
2Since this study is now completed, have the results been published or shared anywhere, and do they change how you would monitor my kidney function if I were in the ICU with AKI?
3The trial focused on patients with Stage 1 or Stage 2 AKI — if my situation matches that, how would a test like this help guide decisions about my treatment compared to the monitoring approach you'd normally use?
4This was labeled as a non-standard phase study, which sometimes means it's more about diagnosis or prediction than a new drug — does that mean the furosemide stress test carries its own risks I should know about, like making kidney function worse?
5If a test like this predicted my AKI was likely to progress to Stage 3, what would actually change about my care plan, and are there interventions that could slow or prevent that progression?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Progression from AKI Stage 1-2 to Stage 3 within 14 days in patients who underwent furosemide stress test